查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1541671

2024-2032 年按药物类型（他汀类药物、胆汁酸螯合剂、胆固醇吸收抑制剂、PCSK9 抑制剂等）、最终用户（医院、诊所等）和地区分類的高血脂药物市场报告

Hyperlipidemia Drugs Market Report by Drug Type (Statins, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, PCSK9 Inhibitors, and Others), End User (Hospitals, Clinics, and Others), and Region 2024-2032
出版日期: | 出版商: IMARC | 英文 146 Pages | 商品交期: 2-3个工作天内

价格

IMARC Group年全球高血脂药物市场规模达227亿美元。

高血脂或高胆固醇是指以血液中高脂肪含量为特征的医学疾病。脂质和/或脂蛋白水平异常升高可导致中风、週边血管疾病、动脉粥状硬化、糖尿病、肥胖、高血压和心血管疾病。它通常是由遗传因素、不健康的生活方式和饮食不当引起的。一些常用的高血脂药物包括他汀类药物、前蛋白转化酶枯草桿菌蛋白酶/Kexin 9 型(PCSK9) 抑制剂、胆汁酸螯合剂、贝特酸衍生物或贝特类药物以及组合和其他降高血脂症药物。这些药物可降低肝臟中胆固醇的产生水平，同时进一步将其从血液中清除。

全球高血脂症盛行率不断上升是推动市场成长的关键因素之一。此外，老年人口的增加也推动了市场的成长，老年人口更容易罹患高胆固醇和心血管疾病。与此一致的是，大众健康意识的提高以及对高胆固醇血症可用治疗替代方案的认识不断增强也有利于市场的成长。此外，各种技术进步，例如具有增强功效的新型药物类别的开发，也是其他生长诱导因素。这些药物可改善内皮功能和动脉粥状硬化斑块的稳定性，并将对细胞的发炎和损伤降至最低。其他因素，包括生物医学领域广泛的研发（R&D）活动，以及全球医疗基础设施的整体改善，预计将进一步推动市场发展。

本报告回答的关键问题

  • 2023年全球高血脂症药物市场规模？ 2024-2032年全球高血脂药物市场的预期成长率是多少？
  • 推动全球高血脂药物市场的关键因素是什么？
  • COVID-19对全球高血脂症药物市场有何影响？
  • 全球高血脂药物市场按药物类型划分是怎样的？
  • 基于最终用户的全球高血脂药物市场的细分情况如何？
  • 全球高血脂药物市场的重点区域有哪些？
  • 全球高血脂药物市场的主要参与者/公司有哪些？

目录

第一章：前言

第 2 章：范围与方法

  • 研究目的
  • 利害关係人
  • 数据来源
    • 主要来源
    • 二手资料
  • 市场预测
    • 自下而上的方法
    • 自上而下的方法
  • 预测方法

第 3 章：执行摘要

第 4 章：简介

  • 概述
  • 主要行业趋势

第 5 章：全球高血脂药物市场

  • 市场概况
  • 市场表现
  • COVID-19 的影响
  • 市场预测

第 6 章：市场区隔：依药物类型

  • 他汀类药物
    • 市场趋势
    • 市场预测
  • 胆汁酸螯合剂
    • 市场趋势
    • 市场预测
  • 胆固醇吸收抑制剂
    • 市场趋势
    • 市场预测
  • PCSK9 抑制剂
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 7 章：市场区隔：按最终用户

  • 医院
    • 市场趋势
    • 市场预测
  • 诊所
    • 市场趋势
    • 市场预测
  • 其他的
    • 市场趋势
    • 市场预测

第 8 章：市场区隔：按地区

  • 北美洲
    • 美国
    • 加拿大
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 澳洲
    • 印尼
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 义大利
    • 西班牙
    • 俄罗斯
    • 其他的
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 其他的
  • 中东和非洲
    • 市场趋势
    • 市场细分：按国家/地区
    • 市场预测

第 9 章：SWOT 分析

  • 概述
  • 优势
  • 弱点
  • 机会
  • 威胁

第 10 章：价值链分析

第 11 章：波特五力分析

  • 概述
  • 买家的议价能力
  • 供应商的议价能力
  • 竞争程度
  • 新进入者的威胁
  • 替代品的威胁

第 12 章：价格分析

第13章：竞争格局

  • 市场结构
  • 关键参与者
  • 关键参与者简介
    • Amgen Inc.
    • AstraZeneca Plc
    • Daiichi Sankyo Company Limited
    • Eli Lilly and Company
    • Esperion Therapeutics Inc.
    • GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
    • Immuron Limited
    • Ionis Pharmaceuticals Inc.
    • Merck & Co. Inc.
    • Pfizer Inc.
    • Sanofi SA
Product Code: SR112024A2685

The global hyperlipidemia drugs market size reached US$ 22.7 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 26.8 Billion by 2032, exhibiting a growth rate (CAGR) of 1.8% during 2024-2032.

Hyperlipidemia, or high cholesterol, refers to a medical ailment characterized by high levels of fats in the bloodstream. It is the abnormal elevation of lipids and/or lipoprotein levels that can lead to stroke, peripheral vascular disease, atherosclerosis, diabetes, obesity, hypertension, and cardiovascular diseases. It is usually caused by genetic factors, unhealthy lifestyles and inadequate diet. Some of the commonly used hyperlipidemia drugs include statins, Proprotein Convertase Subtilisin/Kexin type 9 (PCSK9) inhibitors, bile acid sequestrants, fibric acid derivatives or fibrates and combination and miscellaneous antihyperlipidemic agents. These drugs reduce cholesterol production levels in the liver while further removing it from the bloodstream.

The increasing prevalence of hyperlipidemia across the globe represents one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to high levels of cholesterol and cardiovascular diseases, is also driving the market growth. In line with this, rising health consciousness among the masses and growing awareness regarding the available treatment alternatives for hypercholesterolemia is also favoring the market growth. Additionally, various technological advancements, such as the development of novel drug classes with enhanced efficacy, are acting as other growth-inducing factors. These drugs offer improved endothelial function and stability of atherosclerotic plaques and cause minimal inflammation and damage to the cells. Other factors, including the extensive research and development (R&D) activities in the field of biomedical sciences, along with overall improvements in the healthcare infrastructure across the globe, are anticipated to drive the market further.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hyperlipidemia drugs market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on drug type and end user.

Breakup by Drug Type:

Statins

Bile Acid Sequestrants

Cholesterol Absorption Inhibitors

PCSK9 Inhibitors

Others

Breakup by End User:

Hospitals

Clinics

Others

Breakup by Region:

North America

United States

Canada

Asia Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Amgen Inc., AstraZeneca PLC, Daiichi Sankyo Company Limited, Eli Lilly and Company, Esperion Therapeutics Inc., GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc), Immuron Limited, Ionis Pharmaceuticals Inc., Merck & Co. Inc., Pfizer Inc. and Sanofi S.A.

Key Questions Answered in This Report

  • 1. What was the size of the global hyperlipidemia drugs market in 2023?
  • 2. What is the expected growth rate of the global hyperlipidemia drugs market during 2024-2032?
  • 3. What are the key factors driving the global hyperlipidemia drugs market?
  • 4. What has been the impact of COVID-19 on the global hyperlipidemia drugs market?
  • 5. What is the breakup of the global hyperlipidemia drugs market based on the drug type?
  • 6. What is the breakup of the global hyperlipidemia drugs market based on the end user?
  • 7. What are the key regions in the global hyperlipidemia drugs market?
  • 8. Who are the key players/companies in the global hyperlipidemia drugs market?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Hyperlipidemia Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Type

  • 6.1 Statins
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Bile Acid Sequestrants
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Cholesterol Absorption Inhibitors
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 PCSK9 Inhibitors
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by End User

  • 7.1 Hospitals
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Clinics
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Others
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast

8 Market Breakup by Region

  • 8.1 North America
    • 8.1.1 United States
      • 8.1.1.1 Market Trends
      • 8.1.1.2 Market Forecast
    • 8.1.2 Canada
      • 8.1.2.1 Market Trends
      • 8.1.2.2 Market Forecast
  • 8.2 Asia Pacific
    • 8.2.1 China
      • 8.2.1.1 Market Trends
      • 8.2.1.2 Market Forecast
    • 8.2.2 Japan
      • 8.2.2.1 Market Trends
      • 8.2.2.2 Market Forecast
    • 8.2.3 India
      • 8.2.3.1 Market Trends
      • 8.2.3.2 Market Forecast
    • 8.2.4 South Korea
      • 8.2.4.1 Market Trends
      • 8.2.4.2 Market Forecast
    • 8.2.5 Australia
      • 8.2.5.1 Market Trends
      • 8.2.5.2 Market Forecast
    • 8.2.6 Indonesia
      • 8.2.6.1 Market Trends
      • 8.2.6.2 Market Forecast
    • 8.2.7 Others
      • 8.2.7.1 Market Trends
      • 8.2.7.2 Market Forecast
  • 8.3 Europe
    • 8.3.1 Germany
      • 8.3.1.1 Market Trends
      • 8.3.1.2 Market Forecast
    • 8.3.2 France
      • 8.3.2.1 Market Trends
      • 8.3.2.2 Market Forecast
    • 8.3.3 United Kingdom
      • 8.3.3.1 Market Trends
      • 8.3.3.2 Market Forecast
    • 8.3.4 Italy
      • 8.3.4.1 Market Trends
      • 8.3.4.2 Market Forecast
    • 8.3.5 Spain
      • 8.3.5.1 Market Trends
      • 8.3.5.2 Market Forecast
    • 8.3.6 Russia
      • 8.3.6.1 Market Trends
      • 8.3.6.2 Market Forecast
    • 8.3.7 Others
      • 8.3.7.1 Market Trends
      • 8.3.7.2 Market Forecast
  • 8.4 Latin America
    • 8.4.1 Brazil
      • 8.4.1.1 Market Trends
      • 8.4.1.2 Market Forecast
    • 8.4.2 Mexico
      • 8.4.2.1 Market Trends
      • 8.4.2.2 Market Forecast
    • 8.4.3 Others
      • 8.4.3.1 Market Trends
      • 8.4.3.2 Market Forecast
  • 8.5 Middle East and Africa
    • 8.5.1 Market Trends
    • 8.5.2 Market Breakup by Country
    • 8.5.3 Market Forecast

9 SWOT Analysis

  • 9.1 Overview
  • 9.2 Strengths
  • 9.3 Weaknesses
  • 9.4 Opportunities
  • 9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

  • 11.1 Overview
  • 11.2 Bargaining Power of Buyers
  • 11.3 Bargaining Power of Suppliers
  • 11.4 Degree of Competition
  • 11.5 Threat of New Entrants
  • 11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

  • 13.1 Market Structure
  • 13.2 Key Players
  • 13.3 Profiles of Key Players
    • 13.3.1 Amgen Inc.
      • 13.3.1.1 Company Overview
      • 13.3.1.2 Product Portfolio
      • 13.3.1.3 Financials
      • 13.3.1.4 SWOT Analysis
    • 13.3.2 AstraZeneca Plc
      • 13.3.2.1 Company Overview
      • 13.3.2.2 Product Portfolio
      • 13.3.2.3 Financials
      • 13.3.2.4 SWOT Analysis
    • 13.3.3 Daiichi Sankyo Company Limited
      • 13.3.3.1 Company Overview
      • 13.3.3.2 Product Portfolio
      • 13.3.3.3 Financials
      • 13.3.3.4 SWOT Analysis
    • 13.3.4 Eli Lilly and Company
      • 13.3.4.1 Company Overview
      • 13.3.4.2 Product Portfolio
      • 13.3.4.3 Financials
      • 13.3.4.4 SWOT Analysis
    • 13.3.5 Esperion Therapeutics Inc.
      • 13.3.5.1 Company Overview
      • 13.3.5.2 Product Portfolio
      • 13.3.5.3 Financials
    • 13.3.6 GlaxoSmithKline Pharmaceuticals Limited (GlaxoSmithKline Plc)
      • 13.3.6.1 Company Overview
      • 13.3.6.2 Product Portfolio
      • 13.3.6.3 Financials
      • 13.3.6.4 SWOT Analysis
    • 13.3.7 Immuron Limited
      • 13.3.7.1 Company Overview
      • 13.3.7.2 Product Portfolio
      • 13.3.7.3 Financials
    • 13.3.8 Ionis Pharmaceuticals Inc.
      • 13.3.8.1 Company Overview
      • 13.3.8.2 Product Portfolio
      • 13.3.8.3 Financials
      • 13.3.8.4 SWOT Analysis
    • 13.3.9 Merck & Co. Inc.
      • 13.3.9.1 Company Overview
      • 13.3.9.2 Product Portfolio
      • 13.3.9.3 Financials
      • 13.3.9.4 SWOT Analysis
    • 13.3.10 Pfizer Inc.
      • 13.3.10.1 Company Overview
      • 13.3.10.2 Product Portfolio
      • 13.3.10.3 Financials
      • 13.3.10.4 SWOT Analysis
    • 13.3.11 Sanofi S.A.
      • 13.3.11.1 Company Overview
      • 13.3.11.2 Product Portfolio
      • 13.3.11.3 Financials
      • 13.3.11.4 SWOT Analysis

List of Figures

  • Figure 1: Global: Hyperlipidemia Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Hyperlipidemia Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Hyperlipidemia Drugs Market: Breakup by Drug Type (in %), 2023
  • Figure 4: Global: Hyperlipidemia Drugs Market: Breakup by End User (in %), 2023
  • Figure 5: Global: Hyperlipidemia Drugs Market: Breakup by Region (in %), 2023
  • Figure 6: Global: Hyperlipidemia Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 7: Global: Hyperlipidemia Drugs (Statins) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 8: Global: Hyperlipidemia Drugs (Statins) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 9: Global: Hyperlipidemia Drugs (Bile Acid Sequestrants) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Hyperlipidemia Drugs (Bile Acid Sequestrants) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Hyperlipidemia Drugs (Cholesterol Absorption Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Hyperlipidemia Drugs (Cholesterol Absorption Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Hyperlipidemia Drugs (PCSK9 Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Hyperlipidemia Drugs (PCSK9 Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Hyperlipidemia Drugs (Other Drug Types) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Hyperlipidemia Drugs (Other Drug Types) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Hyperlipidemia Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Hyperlipidemia Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Hyperlipidemia Drugs (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Hyperlipidemia Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Hyperlipidemia Drugs (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Hyperlipidemia Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: North America: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: North America: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: United States: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: United States: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Canada: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Canada: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Asia Pacific: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Asia Pacific: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: China: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: China: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Japan: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Japan: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: India: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: India: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: South Korea: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: South Korea: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: Australia: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: Australia: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Indonesia: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Indonesia: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Others: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Others: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: Europe: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: Europe: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Germany: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Germany: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: France: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: France: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: United Kingdom: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: United Kingdom: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Italy: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Italy: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Spain: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Spain: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Russia: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Russia: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Others: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Others: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Latin America: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Latin America: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: Brazil: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: Brazil: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: Mexico: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: Mexico: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Others: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Others: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Middle East and Africa: Hyperlipidemia Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Middle East and Africa: Hyperlipidemia Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Global: Hyperlipidemia Drugs Industry: SWOT Analysis
  • Figure 72: Global: Hyperlipidemia Drugs Industry: Value Chain Analysis
  • Figure 73: Global: Hyperlipidemia Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hyperlipidemia Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Hyperlipidemia Drugs Market Forecast: Breakup by Drug Type (in Million US$), 2024-2032
  • Table 3: Global: Hyperlipidemia Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 4: Global: Hyperlipidemia Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 5: Global: Hyperlipidemia Drugs Market Structure
  • Table 6: Global: Hyperlipidemia Drugs Market: Key Players